SMi presents its 4th annual conference on...

**Orphan Drugs and Rare Diseases**

Reviewing strategies to increase rare disease research and enhance the development of new treatments

Holiday Inn Regents Park, London UK

---

**Benefits of attending:**

- Learn about *key strategies* and collaborations to accelerate *rare disease clinical drug development*
- Understand how patients and families are *key team players* in improving therapy development
- Discover how gene therapy is a very real factor in clinical trials
- Review how *big pharma* is positioning itself in the emerging orphan drug industry
- Discuss *academic* and *big pharma* perspectives on how to overcome the challenges of rare diseases

**Chairs for 2015:**

- Dr Alastair Kent OBE, Director, Genetic Alliance UK, Chair, Rare Disease UK (RDUK)
- Dr Nicolas Sireau, Chairman & CEO, AKU Society

**Key speakers include:**

- Dr Tim Miller, President & CEO, Abeona Therapeutics
- Dr Anne Marquet, Principal Clinical Scientist, Rare Diseases, Roche Pharma Research and Early Development
- Dr Carlos R. Camozzi, Chief Medical Officer, Orphazyme
- Michael Skynner, Head of Rare Disease External Alliances, Pfizer
- David Boothe, Global Commercial Leader – GSK Rare Diseases, GSK

---

**PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS**

**A: Market access to orphan drugs:**

**Controversies; trends and solutions**

Workshop Leader:

Colette Hamilton, Managing Director, ATP Market Access

8.30am – 12.30pm

**B: The rare disease patient perspective – from regulatory to clinical execution**

Workshop Leaders:

Christa van Kan, Team Lead Clinical Execution, PSR Orphan Experts
Steve Pinder, PhD Director, Envestia Ltd
Nicolas Sireau, PhD, Chairman and CEO, AKU Society

1.30pm – 5.30pm

---

www.orphandrugs-event.com

Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711

**ACADEMIC & GROUP DISCOUNTS AVAILABLE**
Orphan Drugs and Rare Diseases
Day One | Monday 19th October 2015

8.30 Registration & Coffee

9.00 Chair’s Opening Remarks
Dr Nicolas Sireau, Chairman & CEO, AKU Society

OPENING ADDRESS

9.10 Challenges for reimbursement of orphan and ultra orphan and the shifting UK payer landscape
• Routes to reimbursement
• NICE Highly Specialised Technologies programme
Josie Godfrey, Associate Director, Highly Specialised Technologies, National Institute for Health and Care Excellence (NICE), UK

9.50 Patient organisations working collaboratively with the challenges of reimbursement from a patient perspective
• A collaborative approach
• Working in partnership with industry
• Reimbursement and access to high cost therapies
Christine Lavary, Chief Executive, MPS Society UK

10.30 Morning Coffee

11.00 Cost of illness analysis in rare diseases: cystic fibrosis as a model
Professor Milan Macek, Head of Department, Department of Biology and Medical Genetics, National Coordination Centre for Rare Diseases, National Center for Cystic Fibrosis, Charles University Prague

MARKET ACCESS

11.40 DevelopAKUre - a patient-led clinical trial
• How to work closely with patients to develop a clinical trial programme
• Strategies for recruiting patients for successful trials
• Using social media in clinical trials
• How to put together successful collaborations
Dr Nicolas Sireau, Chairman and CEO, AKU Society

12.20 Networking Lunch

1.20 Meeting the challenges of rare diseases - a big pharma perspective
• Listening to patients, care givers and patient groups
• Creative development program design
• Open and early engagement with regulators
David Boothe, Global Commercial Leader – GSK Rare Diseases, GSK

2.00 The academics’ perspectives
• Engaging academic institutions to contribute external expertise to overcome development hurdles
• Drivers for academics to participate in development programs
• Key elements of partnering
Dr Joanna Cox, Head of Business Partnerships, Cranfield University

2.40 Importance of collaboration in rare disease research
• Working in rare disease research presents specific challenges
• One approach to address these challenges is through collaboration
• Pfizer’s collaborative approaches in the area of drug discovery
Michael Skinner, Head of Rare Disease Alliances, Rare Disease Research Unit, Pfizer

3.10 Afternoon Tea

GENE THERAPIES

3.40 Developing gene therapy for orphan disease indications - a perspective from academia
• Gene therapy shows significant efficacy in a number of inherited bone marrow disorders
• These are possible curative genetic medicines for otherwise untreatable diseases
• The move beyond academic clinical trials is still difficult and not yet well charted
• There is increasing interest from industry but the commercial case for rare diseases remains difficult
Professor Bobby Gaspar, Professor of Paediatrics and Immunology, Consultant in Paediatric Immunology, Head, Rare Diseases Theme Head, University College London, Institute of Child Health

4.20 Gene therapy for rare diseases – what we can expect in 2016
• Multiple groups moving rare disease gene therapies into Phase I and II clinical trials
• The gene therapy bubble – 2013-2015 saw large investments in gene therapy companies
• Manufacturing – the next big hurdle on the path to commercialization
Dr Tim Miller, President & CEO, Abeona Therapeutics

5.00 Is global collaboration the answer to reaching all potential patients?
• Is this the way forward for reaching patients and developing and new treatments?
• What resources would be required?
• How would this be coordinated?
Dr Nicolas Sireau, Chairman & CEO, AKU Society

5.40 Chairman’s Closing Remarks and Close of Day One

SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMI offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Alia Matlick, Director on +44 (0) 20 7827 6168 or email: amatlick@smi-online.co.uk

Want to know how you can get involved?
Interested in promoting your services to this market?
Contact Sarah Watson,
SMI Marketing on
+44 20 7827 6134, or email: swatson@smi-online.co.uk

Register online at: www.orphanandrugs-event.com • Alternatively fax
DRUG DEVELOPMENTS & COMMERCIALISATION

9.50 Big pharma and the orphan drug industry
- Analysing the role of big pharma in the emerging orphan drug industry
- Where is their focus going and what does this mean for the industry long term
- What is their current perspective and what is the next step?
Dr Carlos R. Camozzi, Chief Medical Officer, Orphazyme

10.30 Morning Coffee

11.00 Development of an orally available SMN2 splicing modifier for the treatment of SMA: An example of a development program in rare diseases
- An accelerated preclinical and development program
- Coping with heterogeneity in rare diseases
- A unique alliance with a focus on patients
Dr Anne Marquet, Principal Clinical Scientist, Rare Diseases, Roche Pharma Research and Early Development

11.40 The complexity and peculiarities of developing and commercialising advance therapies (ATMPs) for the treatment of rare diseases
- The complexity of translating “traditional” pharma development into ATMP’s...
  - when pharmacology (primary, secondary, safety), toxicology, DMPK, and carcinogenicity are “not applicable” and phase I simply not existing
  - when late stage clinical studies inevitably carry over development risks from untraditional CMC, pre-clinical, and early clinical stages
- Understanding the complexity … of logistics in ATMPs with short shelf-life, requiring delicate transportation conditions, or manufactured/ packedaged for an individual patient
- The complexity … of market access and pricing for treatments to be administered once in a lifetime
- The return-of-investment in the orphan ATMP space
Dr Diego Ardigo, ATMP Project Leader, Corporate Drug Development, R&D, Chiesi Farmaceutici S.p.A.

12.20 Networking Lunch

CASE STUDY

1.20 Zorblisa® (SD-101): A topical therapy in phase 3 for treating the skin effects associated with epidermolysis bullosa (eb)
- Epidermolysis bullosa (EB) is a rare genetic disease that typically manifests at birth or early childhood leading to fragile skin susceptible to blistering and tearing
- There are many genetic and symptomatic variations of EB, but all forms share the common symptom of fragile skin that blisters and tears from the slightest friction or trauma
- EB is chronic, debilating and potentially disfiguring, and patients with EB can have painful wounds and blisters affecting a substantial percentage of their bodies
- There is currently no effective or approved treatment for EB. Current standard of care consists solely of bandaging and wound management to prevent infection and manage patients’ pain
- The Pivotal Phase 3 registration trial is ongoing in the US and EU to evaluate the safety and efficacy of Zorblisa (SD-101), a proprietary and novel topical therapy for the treatment of patients across all subtypes of Epidermolysis Bullosa (EB)
Dr Robert Ryan, President & Chief Executive Officer, Scioderm, Inc.

2.00 The Future of Orphan Drugs: Creating an orphan market for a sustainable future
- Discussing whether the market sustainable
- How can we prepare for the future, what future steps are needed
Josie Godfrey, Associate Director Highly Specialised Technologies and Topic Selection, National Institute for Health and Care Excellence (NICE)
Dr Tim Miller, President & CEO, Abeona Therapeutics

3.10 Development of a drug for GM1-gangliosidosis by a non-profit foundation
- Discovery phase: Working with academic laboratories and spin-off of a commercial entity
- Preclinical development: Outsourcing to commercial service providers vs. academic laboratories
- Clinical development: Selecting the right partners for a micro-company
- Financing the development of a drug for a rare disease
Dr Stephane Demotz, Founder, Dorphan SA, Switzerland

3.50 Patient-empowered pharmaceutical R & D. Building an orphan and ultra-orphan gene therapy pipeline, from research to patient access or marketing authorisation
- The role of patients association in the rare disease field
- The development of an ATMP (gene therapy) as an orphan drug
Dr Didier Caizergues, Head of regulatory Affairs Department, International Regulatory Affairs Department, Genethon

4.30 The real story about rare and ultra-rare disease
- A story that needs to be told by people who are living the nightmare of rare and ultra-rare diseases
- A story of how and why the Foundation was put in place
Terence Hoey, CEO, The Ultra Rare Diseases, Disorder & Disabilities Foundation

5.10 Chairman’s Closing Remarks and Close of Day Two

PANEL DISCUSSION

2.40 Afternoon Tea

3.10 Development of a drug for GM1-gangliosidosis by a non-profit foundation
- Discovery phase: Working with academic laboratories and spin-off of a commercial entity
- Preclinical development: Outsourcing to commercial service providers vs. academic laboratories
- Clinical development: Selecting the right partners for a micro-company
- Financing the development of a drug for a rare disease
Dr Stephane Demotz, Founder, Dorphan SA, Switzerland

ULTRA-RARE DISEASE

4.30 The real story about rare and ultra-rare disease
- A story that needs to be told by people who are living the nightmare of rare and ultra-rare diseases
- A story of how and why the Foundation was put in place
Terence Hoey, CEO, The Ultra Rare Diseases, Disorder & Disabilities Foundation

5.10 Chairman’s Closing Remarks and Close of Day Two

Drugs-event.com

Orphan Drugs and Rare Diseases
Day Two | Tuesday 20th October 2015

 Registration & Coffee

Chairman’s Opening Remarks
Alastair Kent OBE, Director, Genetic Alliance UK, Chair, Rare Disease UK (RDUK)

Putting patients on the team to improve therapy development
- Adaptive Pathways and other innovations will require real world evidence collection
- Patients and families have views on what matters that need to be included
- The benefit: Risk estimation cannot be undertaken effectively without patient input
- Demonstrating value and clinical benefit relies on patient and family experiences being systematically incorporated into MA and HTA processes
Alastair Kent OBE, Director, Genetic Alliance UK, Chair, Rare Disease UK (RDUK)

Supported by
Overview of workshop:
Working through case studies and drawing on the experience of participants, the workshop will explore trends in policy and the reimbursement of orphan drugs and the implications for industry, doctors and patients. The emphasis will be on generating solutions that can both address market conditions and drive patient access to effective orphan drugs.

Benefits of attending:
Keeping people affected by rare diseases at the heart, the workshop will promote sharing of up to the minute information, market trends, payer insights and best practise to support your effective cross functional market entry and strategic market planning. The content will be kept iterative in order to address the specific requirements of participants, it will include new insights on pricing for access and on how to develop a stronger payer value story.

Programme:
8.30 Registration and Coffee
9.00 Opening remarks and introductions
9.10 The Pricing Controversy
   • Price vs cost – payer perspectives
   • Label creep
   • The relationship between pricing policy and patient access
   • Case studies
   • Attaining WIN-WIN
9.50 Payor Trends and Implications
   • Trends in payer policy and coverage
   • Trends in HTA evaluation
   • Understanding conditions for reimbursement
   • Implications for industry
10.30 Coffee
11.00 Redefining Value
   • Evolving understanding of benefit versus cost
   • QALY limitations and alternatives
   • Adoption of multi-criteria decision analysis
   • Solutions that work for patients, doctors, industry and payers
11.40 Evidence Generation
   • Addressing challenges in demonstrating safety and efficacy when working with low patient numbers
   • Creative ways to assimilate data
   • The opportunities and limitations of real world evidence
   • Evidence generation solutions for orphan drugs
12.20 Closing remarks
12.30 End of workshop

About the workshop leader:
Colette is a global market access, reimbursement and health economics specialist, with a proven track record in extending the reach of health transforming technologies to patients. Before transitioning to healthcare industry in 2002, she was an international healthcare advisor with PwC following eleven years of health services management experience in the UK. She has successfully delivered reimbursement projects in North America; Asia Pacific; Europe and Africa. She is experienced in working with orphan drugs, in particular, with applications in immunology and cancer treatment. Colette has a clinically qualified, with an MBA and an MSc in Psychological Studies. Colette is also Vice President of Health Economics and Reimbursement for Evidence for Access, a new venture with Tech Mahindra, a multi-billion pound technology company, providing end to end real world evidence generation solutions for pharma and medical device companies.

About the organisation:
ATP Market Access, the business name of ATP Consulting Ltd., is a niche consultancy practise, founded in 2003 to deliver healthcare transformation by accelerating access to value adding health technologies.
Overview of workshop:

This workshop will provide insights into the orphan drug regulatory landscape towards clinical execution and its accompanying challenges, with emphasis on the rare disease patient’s perspective. It includes insights into the current possibilities and challenges within the regulatory framework plus the necessary requirements to transform the regulatory strategy into feasible clinical development planning. Furthermore, the crucial role of the patient and the patient advocacy groups in all aspects of Clinical Development Planning and the organisational and practical challenges during execution of the clinical trials will be considered.

Benefits of attending:

• To get insight into the overall process from the regulatory perspective (e.g. orphan drug designation) towards running clinical studies in rare disease patients.
• To successfully transform regulatory strategies into practical clinical development planning and subsequently running successful clinical trials in rare disease indications.
• To understand how to collaborate with patient advocacy groups in the most successful way for your orphan drug development program.
• To learn the importance of potential strategies to lower patient burden and thereby increase patient recruitment and retention in rare disease studies and thus benefit overall study success rate.

Programme:

1.30 Registration and Coffee
2.00 Opening remarks and introductions
2.10 Regulatory framework & how to successfully transform regulatory strategies into practical clinical development planning (Steve Pinder)
   • Brief outline of Orphan Drug regulations
   • Common misinterpretations of orphan drug legislations
   • Regulatory strategies vs Clinical development strategies
3.30 Coffee
3.45 The crucial role of patient advocacy groups in a successful orphan drug development program (Nick Sireau)
   • Public/private funding & crowd funding
   • Role of patient advocacy groups in rare disease clinical trials
4.30 Lowering patient burden & practical/logistical challenges to ensure successful clinical study execution (Christa van Kan)
   • Patient recruitment & retention strategies
   • Lowering patient burden
   • Logistical/practical challenges
5.15 Closing remarks
5.30 End of workshop

About the workshop leaders:

Christa van Kan has more than 20 years experience in managing clinical trials in a broad range of diseases, including many orphan and paediatric indications. Christa has developed several innovative recruitment & retention strategies, specifically focussed on Orphan Diseases.

Dr Nicolas Sireau is Chairman and CEO of the AKU Society, a medical charity that works to find a cure for and support patients with AKU (also called Black Bone Disease), an ultra rare disease that affects his two sons (www.akusociety.org).

Steve Pinder In 2007 Steve founded Envestia Ltd with business partner Dr Ian Dews, a pharmaceutical physician and former full-time clinical investigator. Steve is one of the regulatory consultants for PSR Orphan Experts and as such been involved in a variety of regulatory projects for orphan drugs.
DELEGATE DETAILS
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.

Title: __________________________     Forename: ______________
Surname: _________________________
Job Title: ________________________
Department/Division: ______________
Company/Organisation: ____________
Email: ___________________________
Company VAT Number: ____________
Address (If different from above):  

ACCO UNTS DEPT
I agree to be bound by SMi’s Terms and Conditions of Booking.
Signature: ____________________________     Date: ____________
Switchboard:

PAYMENT
Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-153 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment:

- UK BACS
  Sort Code: 300009
  Account: 00936418

- Wire Transfer
  Lloyds TSB Bank plc, 39Threadneedle Street, London, EC2R 8AU
  Swift (BIC): LOYDGB21013, Account: 00936418
  IBAN GB48 LOYD 3000 0900 9364 18

- Cheque
  We can only accept Sterling cheques drawn on a UK bank.

- Credit Card
  Visa     MasterCard     American Express
  Credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received:

- Cheque
  Make payable to SMi Group Ltd. Drawn on a UK bank. Please quote reference P-153 and the delegate’s name. Bookings

- Credit Card
  Visa     MasterCard
  Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-153 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment:

- UK BACS
  Sort Code: 300009
  Account: 00936418

- Wire Transfer
  Lloyds TSB Bank plc, 39Threadneedle Street, London, EC2R 8AU
  Swift (BIC): LOYDGB21013, Account: 00936418
  IBAN GB48 LOYD 3000 0900 9364 18

- Cheque
  We can only accept Sterling cheques drawn on a UK bank.

- Credit Card
  Visa     MasterCard     American Express
  Credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received:

- Cheque
  Make payable to SMi Group Ltd. Drawn on a UK bank. Please quote reference P-153 and the delegate’s name. Bookings

- Credit Card
  Visa     MasterCard

VENDOR
Holiday Inn Regents Park Hotel, Carburton Street, London, W1W 5EE

PHONE on +44 (0) 870 9090 711

If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk